Supernus Pharmaceuticals Inc. (SUPN) exhibits 89.6% gross margins and -4.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 6.5% implied options volatility.
Sustained 89.6% gross profitability converts into -8.7% operating margin and -4.5% ROIC, outpacing sector cost of capital.
ROIC: -4.5% // GM: 89.6%YoY revenue trajectory of +8.6% paired with 1.89% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.6% // FCF YLD: 1.89%Altman Z-Score of 4.84 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.84 // F-SCORE: 7/9Trading at 24.0x trailing P/E (22.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.5% implied move with a 0.82 put/call ratio around $41.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.82Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -5.4% net margins.
NET MARGIN: -5.4% // D/E: 0.15x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SUPN & activate live FRED threshold breach alerts.